Janssen Biotech, Inc. announces collaborative development and worldwide license agreement for investigational anti-cancer drug, PCI-32765
Compound in development for multiple B-cell hematologic malignancies...
8 December 2011 | By Johnson & Johnson
Compound in development for multiple B-cell hematologic malignancies...